1379302-09-6

Basic information

• Product Name: Methyl 2-chloro-3-nitropyridine-4-carboxylate
• Synonyms: Methyl 2-chloro-3-nitropyridine-4-carboxylate;Methyl 2-chloro-3-nitroisonicotinate
• CAS NO: 1379302-09-6
• Molecular Formula: C7H5ClN2O4
• Molecular Weight: 216.5786
• Mol File: 1379302-09-6.mol

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: Methyl 2-chloro-3-nitropyridine-4-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 2-chloro-3-nitropyridine-4-carboxylate(1379302-09-6)
• EPA Substance Registry System: Methyl 2-chloro-3-nitropyridine-4-carboxylate(1379302-09-6)

Safety Data

• Hazardous Substances Data: 1379302-09-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 2-chloro-3-nitropyridine-4-carboxylate is used as a key intermediate in the synthesis of various drugs. Its reactivity enables the formation of different derivatives, contributing to the development of new pharmaceutical agents with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, Methyl 2-chloro-3-nitropyridine-4-carboxylate serves as a building block for the synthesis of pesticides. Its ability to form various derivatives allows for the creation of effective pest control agents, enhancing crop protection and yield.
Safety Precautions:
It is crucial to handle Methyl 2-chloro-3-nitropyridine-4-carboxylate with care due to its toxic nature. Exposure to this compound can result in skin and eye irritation, necessitating proper safety measures during its use and storage.

Upstream product

• 23056-39-5 2-chloro-3-nitro-4-methylpyridine 
• 67-56-1 methanol 
• 353281-15-9 2-chloro-3-nitroisonicotinic acid 

Relevant articles and documents

1-CYANO-PYRROLIDINE DERIVATIVES AS INHIBITORS OF USP30.

The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylatingenzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C- terminal hydrolase 30 or Ubiquitin Specific Peptidase 30 (USP30). The invention further relates to the use of DUB inhibitors in the treatment of conditions involving mitochondrial dysfunction and cancer. Compounds of the invention include compounds having the formula (I) (I) or a pharmaceutically acceptable salt thereof, wherein R1, R 2, R 3, m, L and X are as defined herein.

NITROGENATED HETEROCYCLIC COMPOUND

The present invention provides a compound having a PDE2A selective inhibitory action, which is useful as an agent for the prophylaxis or treatment of schizophrenia, Alzheimer's disease and the like. The present invention is a compound represented by the formula (1): wherein each symbol is as described in the specification, or a salt thereof.